Randomized study suggests further evaluation of maraviroc in PrEP strategies may be warranted.
Greater participant satisfaction with cabotegravir injections administered every 12 weeks vs oral once-daily tablets, but pharmacokinetic analysis suggests shorter dosing interval may be required to provide adequate protection.
Nonadherence and lack of efficacy observed in subset of women younger than 21 years of age.
Switch to the novel NRTI coformulation FTC/TAF associated with improvements in bone and renal biomarkers.
Results in line with earlier findings of EARNEST and SECOND-LINE studies.
Intramuscular cabotegravir regimen administered every 4 or 8 weeks showed similar virologic efficacy as oral cabotegravir regimen with mild injection-site reactions.
Lopinavir/ritonavir-containing 3-drug ART regimen started in pregnancy associated with significantly lower whole-body bone mineral content in newborns vs zidovudine monotherapy plus single-dose nevirapine with a tenofovir DF/emtricitabine tail.
First assessment of dolutegravir activity in pregnant women finds exposures vary within the normal range.
Numerous other factors associated with fracture risk, including past fracture or osteonecrosis and lower CD4+ cell count.
Efficacy was comparable to that of efavirenz in the overall study group; drug-related AEs, specific CNS events less frequent with doravirine vs efavirenz.
Adherence to treatment remains most important predictor of response.
BMD recovery rate appears slower in adults aged 25 years and older.
At Week 96, incident chronic kidney disease was reported in 0.1% of patients receiving TAF vs 1.6% of patients receiving TDF.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.